Search Results - "Kabraji, Sheheryar"

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer by Wang, Qiwei, Bergholz, Johann S., Ding, Liya, Lin, Ziying, Kabraji, Sheheryar K., Hughes, Melissa E., He, Xiadi, Xie, Shaozhen, Jiang, Tao, Wang, Weihua, Zoeller, Jason J., Kim, Hye-Jung, Roberts, Thomas M., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Dillon, Deborah A., Winer, Eric P., Lin, Nancy U., Zhao, Jean J.

“…PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors with BRCA mutations. However, the impact of this class of…”
Get full text

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? by Kabraji, Sheheryar, Ni, Jing, Lin, Nancy U, Xie, Shaozhen, Winer, Eric P, Zhao, Jean J

“…The brain is the most common site of first metastasis for patients with HER2-positive breast cancer treated with HER2-targeting drugs. However, the development…”
Get full text

p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases by Ni, Jing, Kabraji, Sheheryar, Xie, Shaozhen, Wang, Yanzhi, Pan, Peichen, He, Xiaofang, Liu, Zongming, Leone, Jose Palbo, Long, Henry W., Brown, Myles A., Winer, Eric P., Dillon, Deborah A. R., Lin, Nancy U., Zhao, Jean J.

“…Approximately 50% of patients with metastatic HER2-positive (HER2+) breast cancer develop brain metastases (BCBMs). We report that the tumor suppressor p16…”
Get full text

Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method by Liu, Zongming, Wang, Yanzhi, Kabraji, Sheheryar, Xie, Shaozhen, Pan, Peichen, Liu, Zhenning, Ni, Jing, Zhao, Jean J.

“…Breast cancer brain metastasis (BCBM) remains a major clinical problem. Approximately 10–16% of patients with breast cancer develop brain metastases (BCBM)…”
Get full text

Temporal and spatial topography of cell proliferation in cancer by Gaglia, Giorgio, Kabraji, Sheheryar, Rammos, Danae, Dai, Yang, Verma, Ana, Wang, Shu, Mills, Caitlin E., Chung, Mirra, Bergholz, Johann S., Coy, Shannon, Lin, Jia-Ren, Jeselsohn, Rinath, Metzger, Otto, Winer, Eric P., Dillon, Deborah A., Zhao, Jean J., Sorger, Peter K., Santagata, Sandro

“…Proliferation is a fundamental trait of cancer cells, but its properties and spatial organization in tumours are poorly characterized. Here we use highly…”
Get full text

JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers by Facompre, Nicole D, Harmeyer, Kayla M, Sole, Xavier, Kabraji, Sheheryar, Belden, Zachary, Sahu, Varun, Whelan, Kelly, Tanaka, Koji, Weinstein, Gregory S, Montone, Kathleen T, Roesch, Alexander, Gimotty, Phyllis A, Herlyn, Meenhard, Rustgi, Anil K, Nakagawa, Hiroshi, Ramaswamy, Sridhar, Basu, Devraj

“…The degree of heterogeneity among cancer stem cells (CSC) remains ill-defined and may hinder effective anti-CSC therapy. Evaluation of oral cancers for such…”
Get full text

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer by Kabraji, Sheheryar, Solé, Xavier, Huang, Ying, Bango, Clyde, Bowden, Michaela, Bardia, Aditya, Sgroi, Dennis, Loda, Massimo, Ramaswamy, Sridhar

“…Background Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple…”
Get full text

Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma by McKee, Chad M, Xu, Danmei, Cao, Yunhong, Kabraji, Sheheryar, Allen, Danny, Kersemans, Veerle, Beech, John, Smart, Sean, Hamdy, Freddie, Ishkanian, Adrian, Sykes, Jenna, Pintile, Melania, Milosevic, Michael, van der Kwast, Theodorus, Zafarana, Gaetano, Ramnarine, Varune Rohan, Jurisica, Igor, Mallof, Chad, Lam, Wan, Bristow, Robert G, Muschel, Ruth J

“…Prostate adenocarcinoma (CaP) patients are classified into low-, intermediate-, and high-risk groups that reflect relative survival categories. While there are…”
Get full text

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer by Grinshpun, Albert, Russo, Douglas, Ma, Wen, Verma, Ana, Hermida-Prado, Francisco, Sherman, Shira, Gaglia, Giorgio, Kabraji, Sheheryar, Kirkner, Gregory, Hughes, Melissa E., Lin, Nancy U., Sandusky, Zachary, Nardone, Agostina, Guarducci, Cristina, Nguyen, Quang-De, Santagata, Sandro, Nagy, Zsuzsanna, Jeselsohn, Rinath

“…The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone…”
Get full text

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth by Alves, Cleidson P., Dey-Guha, Ipsita, Kabraji, Sheheryar, Yeh, Albert C., Talele, Nilesh P., Solé, Xavier, Chowdhury, Joeeta, Mino-Kenudson, Mari, Loda, Massimo, Sgroi, Dennis, Borresen-Dale, Anne-Lise, Russnes, Hege G., Ross, Kenneth N., Ramaswamy, Sridhar

“…Abstract Human tumor growth depends on rapidly dividing cancer cells driving population expansion. Even advanced tumors, however, contain slowly proliferating…”
Get full text

AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast by Kabraji, Sheheryar, Sole, Xaiver, Huang, Ying, Bango, Clyde, Sgroi, Dennis, Loda, Massimo, Ramaswamy, Sridhar

“…Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression…”
Get full text

Keeping It in the Family: HER3 as a Target in Brain Metastases by Kabraji, Sheheryar, Lin, Nancy U

“…In 180 patients with metastatic breast cancer and non-small cell lung cancer (NSCLC), HER3 expression was found in >70% of brain metastases (BM)…”
Get full text

Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications by Bergholz, Johann S, Wang, Qiwei, Kabraji, Sheheryar, Zhao, Jean J

“…Small-molecule targeted therapies have demonstrated outstanding potential in the clinic. These drugs are designed to minimize adverse effects by selectively…”
Get full text

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer by Gainor, Justin F, Varghese, Anna M, Ou, Sai-Hong Ignatius, Kabraji, Sheheryar, Awad, Mark M, Katayama, Ryohei, Pawlak, Amanda, Mino-Kenudson, Mari, Yeap, Beow Y, Riely, Gregory J, Iafrate, A John, Arcila, Maria E, Ladanyi, Marc, Engelman, Jeffrey A, Dias-Santagata, Dora, Shaw, Alice T

“…Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of non-small cell lung cancer (NSCLC). Recently, several case reports…”
Get full text

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases by Kabraji, Sheheryar, Ni, Jing, Sammons, Sarah, Li, Tianyu, Van Swearingen, Amanda E D, Wang, Yanzhi, Pereslete, Alyssa, Hsu, Liangge, DiPiro, Pamela J, Lascola, Chris, Moore, Heather, Hughes, Melissa, Raghavendra, Akshara S, Gule-Monroe, Maria, Murthy, Rashmi K, Winer, Eric P, Anders, Carey K, Zhao, Jean J, Lin, Nancy U

“…Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded…”
Get full text

PI3Kβ controls immune evasion in PTEN-deficient breast tumours by Bergholz, Johann S., Wang, Qiwei, Wang, Qi, Ramseier, Michelle, Prakadan, Sanjay, Wang, Weihua, Fang, Rong, Kabraji, Sheheryar, Zhou, Qian, Gray, G. Kenneth, Abell-Hart, Kayley, Xie, Shaozhen, Guo, Xiaocan, Gu, Hao, Von, Thanh, Jiang, Tao, Tang, Shuang, Freeman, Gordon J., Kim, Hye-Jung, Shalek, Alex K., Roberts, Thomas M., Zhao, Jean J.

“…Loss of the PTEN tumour suppressor is one of the most common oncogenic drivers across all cancer types 1 . PTEN is the major negative regulator of PI3K…”
Get full text

Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy by Corti, Chiara, Binboğa Kurt, Busem, Koca, Beyza, Rahman, Tasnim, Conforti, Fabio, Pala, Laura, Bianchini, Giampaolo, Criscitiello, Carmen, Curigliano, Giuseppe, Garrido-Castro, Ana C., Kabraji, Sheheryar K., Waks, Adrienne G., Mittendorf, Elizabeth A., Tolaney, Sara M.

Get full text

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases by Ni, Jing, Wang, Yanzhi, Diala, Irmina, Kabraji, Sheheryar, Freedman, Rachel, Lin, Nancy, Zhao, Jean

“…Abstract Up to half of patients with metastatic HER2-positive breast cancer will develop brain metastases. Breast cancer brain metastases (BCBM) are a major…”
Get full text

Abstract 4: Temporal and spatial topography of cell proliferation in cancer by Gaglia, Giorgio, Kabraji, Sheheryar, Argyropoulou, Danae, Dai, Yang, Bergholz, Johann, Coy, Shannon, Lin, Jia-Ren, Winer, Eric P., Dillon, Deborah, Zhao, Jean J., Sorger, Peter K., Santagata, Sandro

“…Abstract Uncontrolled cell proliferation is a defining feature of malignancy. Current understanding of proliferation, particularly in humans, derives primarily…”
Get full text

Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases by Ni, Jing, Kabraji, Sheheryar, Xie, Shaozhen, Wang, Yanzhi, Pan, Peichen, He, Xiaofang, Liu, Zongming, Long, Henry, Brown, Myles, Winer, Eric P., Dillon, Deborah, Lin, Nancy, Zhao, Jean

“…Abstract Approximately 50% of patients with metastatic HER2-positive (HER2+) breast cancer develop brain metastases (BCBMs). To identify predictors of response…”
Get full text